Ginkgo Bioworks will go public in SPAC deal worth over $1.6B

By LabPulse.com staff writers

September 14, 2021 -- Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition company (SPAC).

The deal was approved by Soaring Eagle's shareholders on September 14. Subject to the satisfaction or waiver of other customary closing conditions, Soaring Eagle anticipates that it will complete its domestication to Delaware on September 15 and then close the business combination with Gingko on September 16. It will then change its name to Ginkgo Bioworks Holdings.

The combined company's shares of Class A common stock and public warrants are expected to begin trading on the New York Stock Exchange on September 17 under the ticker symbols "DNA" and "DNA.WS," respectively.

Everlywell, Gingko Bioworks to distribute COVID-19 antigen test
Everlywell has signed an agreement with Ginkgo Bioworks to distribute Access Bio's CareStart COVID-19 antigen test to workplaces, clinics, schools, government...
Gingko raises $70M, plans NGS deployment against coronavirus
Cell programming company Ginkgo Bioworks has announced $70 million in funding to use its technology to address the ongoing COVID-19 pandemic.

Copyright © 2021 LabPulse.com

Last Updated bc 9/15/2021 1:08:53 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current